Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Research demonstrates new computer software to help diagnose cancer cells

Research demonstrates new computer software to help diagnose cancer cells

Yashoda Cancer Institute uses Varian Clinac medical linear accelerator for radiotherapy treatments

Yashoda Cancer Institute uses Varian Clinac medical linear accelerator for radiotherapy treatments

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Scientists reveal structure of protein complex involved in liver and colon cancers

Scientists reveal structure of protein complex involved in liver and colon cancers

Genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma

Genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Celsion acquires all assets of EGEN

Celsion acquires all assets of EGEN

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Poll: Fixing vets' health care high priority

Poll: Fixing vets' health care high priority

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Antiviral therapy may prevent hepatitis B virus from developing into hepatocellular carcinoma

Antiviral therapy may prevent hepatitis B virus from developing into hepatocellular carcinoma

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

New vaccine effective at preventing lung cancer in mice

New vaccine effective at preventing lung cancer in mice

Researchers develop antibodies that reduce liver damage, recovers liver function

Researchers develop antibodies that reduce liver damage, recovers liver function

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.